Identification of immunodominant regions among promiscuous HLA-DR–restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3
- 1 February 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (3) , 1038-1044
- https://doi.org/10.1182/blood-2002-03-0933
Abstract
The molecular characterization of the CD4+ T-cell epitope repertoire on human tumor antigens would contribute to both clinical investigation and cancer immunotherapy. In particular, the identification of promiscuous epitopes would be beneficial to a large number of patients with neoplastic diseases regardless of their HLA-DR type. MAGE-3 is a tumor-specific antigen widely expressed in solid and hematologic malignancies; therefore, is an excellent candidate antigen. We used a major histocompatability complex (MHC) class II epitope prediction algorithm, the TEPITOPE software, to predict 11 sequence segments of MAGE-3 that could form promiscuous CD4+ T-cell epitopes. In binding assays, the synthetic peptides corresponding to the 11 predicted sequences bound at least 3 different HLA-DR alleles. Nine of the 11 peptides induced proliferation of CD4+ T cells from both healthy subjects and melanoma patients. Four immunodominant regions (residues 111-125, 146-160, 191-205, and 281-295), containing naturally processed epitopes, were recognized by most of the donors, in association with 3 to 4 different HLA-DR alleles, thus covering up to 94% of the alleles expressed in whites. On the contrary, the other promiscuous regions (residues 161-175 and 171-185) contained epitopes not naturally processed in vitro. The immunodominant epitopes identified will be useful in the design of peptide-based cancer vaccines and in the study of the functional state of tumor-specific CD4+ T cells in patients bearing tumors expressing MAGE-3.Keywords
This publication has 25 references indexed in Scilit:
- CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic CellsImmunity, 2000
- Monoclonal antibody 57B stains tumor tissues that express geneMAGE-A4International Journal of Cancer, 2000
- CD4+T cells eliminate MHC class II-negative cancer cellsin vivoby indirect effects of IFN-γProceedings of the National Academy of Sciences, 1999
- Human Melanoma Cells Transfected with the B7-2 Co-Stimulatory Molecule Induce Tumor-Specific CD8+Cytotoxic T LymphocytesIn VitroHuman Gene Therapy, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3International Journal of Cancer, 1995
- Dominance and Crypticity of T Cell Antigenic DeterminantsAnnual Review of Immunology, 1993
- Identification of a CD4 binding site on the β2 domain of HLA-DR moleculesNature, 1992
- [19] Selection of T cell epitopes and vaccine engineeringPublished by Elsevier ,1991
- General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.Proceedings of the National Academy of Sciences, 1985